地舒单抗联合雷洛昔芬对绝经后骨质疏松患者性激素结合蛋白、骨硬化蛋白水平的影响

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (997 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effects of desucumab combined with raloxifene on the levels of sex hormone binding protein (SHBG) and osteosclerosis protein (SOST) in postmenopausal osteoporosis patients. Methods A total of 140 postmenopausal osteoporosis patients admitted to the Third Medical Center of PLA General Hospital from May 2022 to May 2023 were selected and randomly divided into a control group and a study group, with 70 cases in each group. The control group was treated with raloxifene for 1 year, 60 mg/time, once/day orally, while the study group received treatment of a combination of raloxifene and desucumab for 1 year. The relevant indicators before and after treatment were collected, and the clinical effects of the two groups were compared and analyzed. Results After 1 year of treatment, the effective rate of the study group was significantly higher than that in the control group(94.29% vs. 82.86%), and the difference between the two groups was statistically significant (P<0.05).Compared with before treatment, the expression levels of estradiol (E₂), follicle stimulating hormone (FSH), luteinizing hormone (LH), bone density, bone mineral content, superoxide dismutase (SOD), and glutathione (GSH) in the two groups increased after treatment, and the study group was significantly higher than the control group, with statistical significance (P<0.05). The expression levels of malondialdehyde (MDA), SHBG, SOST, type I collagen cross-linked amino terminal peptide (NTX1), type I collagen cross-linked carboxyl terminal peptide (CTX1), tartaric acid phosphatase 5b (TRACP5b), and osteocalcin (BGP) were reduced, and the study group was significantly lower than the control group, with statistical significance (P<0.05). Conclusions The combined use of desucumab and raloxifene can improve bone metabolism and oxidative stress, reduce the expression of SHBG and SOST in postmenopausal osteoporosis patients.

Key words： postmenopausal osteoporosis desucumab raloxifene sex hormone binding protein osteosclerosis protein

Received: 03 January 2024

ZTFLH:

R453.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YAN Xiujie
	ZHUANG Wenyuan
	ZHANG Rui
	ZHANG Yue
	ZHANG Hao

Cite this article:

YAN Xiujie,ZHUANG Wenyuan,ZHANG Rui等. Effect of desucumab combined with raloxifene on SHBG and SOST Levels in postmenopausal patients with osteoporosis[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(8): 650-653.

URL:

https://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR https://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2024/V35/I8/650

[1]	Arceo R M, Camacho P M. Postmenopausal osteoporosis: latest guidelines[J].Endocrinol Metab Clin North Am, 2021,50(2):167-178.
[2]	Reid I R. A broader strategy for osteoporosis interventions[J]. Nat Rev Endocrinol,2020,16(6):333-339.
[3]	Wu D, Cline S A, Shashkova E, et al. T-Cell mediated inflammation in postmenopausal osteoporosis[J]. Front Immunol, 2021,(30)12:687551.
[4]	王锐,王梦莹,王莎莎. 炔雌醇环丙孕酮联合雷洛昔芬对多囊卵巢综合征不孕患者卵巢功能和妊娠率的影响[J]. 中国实用医刊,2021,48(21):116-119.
[5]	中华医学会骨质疏松和骨矿盐疾病分会. 地舒单抗在骨质疏松症临床合理用药的中国专家建议[J]. 中华骨质疏松和骨矿盐疾病杂志,2020,13(6):499-508.
[6]	中国老年学和老年医学学会骨质疏松分会妇产科专家委员会与围绝经期骨质疏松防控培训部. 围绝经期和绝经后妇女骨质疏松防治专家共识[J]. 中国临床医生杂志,2020,48(8):903-908.
[7]	王勤俭,李泊泊,姜幸福,等. 骨瓜提取物注射液联合常规治疗对绝经后骨质疏松症患者的临床疗效[J]. 中成药,2023,45(10):3252-3256.
[8]	马学智,马勇,郭杨. 补肾健脾活血法治疗绝经后骨质疏松症疗效的Meta分析[J]. 中国骨质疏松杂志,2022,28(4):527-535.
[9]	谢丽华,柴昊,叶云金,等. 续苓健骨颗粒治疗肾虚血瘀型绝经后骨质疏松症的疗效及转录机制研究[J]. 中国骨质疏松杂志,2022,28(4):558-561,600.
[10]	汤淑女,尹香君,余卫,等. 中国40岁及以上绝经后女性骨质疏松症患病率及其影响因素研究[J]. 中华流行病学杂志,2022,43(4):509-516.
[11]	高倩,陈云霞,代嘉,等. 特立帕肽联合雷洛昔芬对绝经后骨质疏松症患者骨代谢异常的改善效果[J]. 疑难病杂志,2020,19(3):257-260,265.
[12]	吴海燕. 雷洛昔芬联合碳酸钙D3治疗绝经后骨质疏松症的临床效果评价[J]. 康颐,2021(14):175.
[13]	孙通华,赵温倩,赵斌,等. 理气固本法治疗绝经后骨质疏松症临床观察[J]. 光明中医,2021,36(3):382-386.
[14]	赵强,段涤云. 骨松康合剂联合地诺单抗治疗绝经后骨质疏松症的临床研究[J]. 现代药物与临床,2021,36(10):2115-2118.
[15]	伍海艳,吴荣艳,钟凤元,等. 雌激素代谢紊乱对老年女性骨质疏松患者的影响[J]. 中国老年学杂志,2021,41(12):2567-2569.
[16]	杨洛,陈林,卢春燕,等. 射频消融术联合地舒单抗治疗血液透析患者伴三发性甲状旁腺功能亢进和骨质疏松1例[J]. 临床肾脏病杂志,2022,22(3):259-262.
[17]	赵强,王建武,杜晓盼. 唑来膦酸及地舒单抗治疗绝经后骨质疏松症的疗效及安全性分析[J]. 山西医药杂志,2021,50(13):2039-2040.
[18]	林家民,李娟,张帆. 唑来膦酸钠联合碳酸钙D3片治疗骨质疏松症的疗效及其骨生化指标的变化[J]. 华中科技大学学报(医学版),2021,50(6):756-760.
[19]	杨云凤,刘菊华,吴碧华,等. 有氧运动联合锝[99Tc]-亚甲基二膦酸盐对老年骨质疏松骨密度及血清抗酒石酸酸性磷酸酶5b的影响[J]. 安徽医药,2020,24(1):128-131.
[20]	曹德云,王艳铭,刘丽,等. 氯膦酸二钠联合骨化三醇治疗绝经后骨质疏松的疗效及对血清IGF-BP-3、SHBG的影响[J]. 西部医学,2020,32(2):238-241.
[21]	赵会荣,李思源,李军,等. 新疆绝经后2型糖尿病女性SOST蛋白表达在骨质疏松中诊断价值的研究[J]. 中国骨质疏松杂志,2021,27(1):31-35.